Candel Therapeutics closed at $9.05 on Nov 4, up 2.61%, 34.2% below its 52-week closing high. Volume of 993.8K shares was 0.93× its 20-day average (close to normal).
Split-adjusted performance: -8.3% over one month, +18.6% over six months, +73.4% over one year.
Short interest was 12.8M shares at the Oct 15 settlement, down 1.8% from the prior report (21.5% of float, 14.1 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| CADLCandel Therapeutics | $9.05 | +2.61% | +18.6% | — | — | — | $692.5M | |
| AURAAura Biosciences | $6.65 | +6.57% | −19.8% | — | — | — | $689.6M | Compare |
| SLDBSolid Biosciences | $6.52 | +3.82% | −9.4% | — | — | — | $699.1M | Compare |
| FDMT4D Molecular Therapeutics | $12.28 | +2.76% | +17.9% | +25106.7% | −1929.0% | — | $678.4M | Compare |
| ATTOAttovia Therapeutics | $15.60 | +2.16% | — | — | — | — | $712.2M | Compare |
| SANASana Biotechnology | $2.56 | +4.92% | −29.7% | — | — | — | $766.4M | Compare |
| DNAGinkgo Bioworks Holdings | $11.65 | +8.27% | +15.6% | −48.5% | −231.7% | — | $784.5M | Compare |
| CGEMCullinan Therapeutics | $12.49 | −20.70% | −16.7% | — | — | — | $803.8M | Compare |
| ENTXEntera Bio | $3.11 | +1.97% | +148.8% | — | — | — | $540.9M | Compare |
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
